Clinical Trials Logo

Pulmonary Hypertension clinical trials

View clinical trials related to Pulmonary Hypertension.

Filter by:

NCT ID: NCT03794583 Enrolling by invitation - Clinical trials for Chronic Obstructive Pulmonary Disease

Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)

PERFECTOLE
Start date: December 21, 2018
Phase: Phase 3
Study type: Interventional

This open-label study will evaluate the safety of continued therapy with inhaled treprostinil in subjects who have completed Study RIN-PH-304. This study hypothesizes that long-term safety findings will be similar to those observed in the randomized, placebo-controlled, double-blind, adaptive study 'A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients with Pulmonary Hypertension due to Chronic Obstructive Pulmonary Disease (PH-COPD)(RIN-PH-304).

NCT ID: NCT03787082 Not yet recruiting - Clinical trials for Pulmonary Hypertension

Chlorhexidine Mouthwash and Oral Nitrate in Adults With Pulmonary Hypertension

Start date: February 2019
Phase: Phase 1
Study type: Interventional

This is an open-label, single-center study to examine distinguishing features of the structure and function of the oral and gut microbiome in volunteers with PH in the breakdown of oral nitrate and effect on hemodynamics.

NCT ID: NCT03780803 Recruiting - Clinical trials for Pulmonary Hypertension

Effect of Home Rehabilitation on State of Patients With PAH, HFREF and IHD

Start date: February 1, 2016
Phase: N/A
Study type: Interventional

The aim of the study is to evaluate the influence of physical training and respiratory rehabilitation performed by patients at home on quality of life, symptoms, physical endurance, force of respiratory and skeletal muscles and body mass composition in patients with pulmonary arterial hypertension (PAH) or left ventricular heart failure with reduced ejection fraction - HFREF), or ischemic heart disease and evaluation the number of stem cells, natural lymphoid cells and distribution of subpopulations of monocytes (including proangiogenic monocytes) in examined persons and evaluation of theirs eventual influence of the course of disease.

NCT ID: NCT03763045 Active, not recruiting - Clinical trials for Pulmonary Hypertension

Sildenafil in Hemodialysis Patients With Pulmonary Hypertension

Start date: December 2, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

Sildenafil is a phosphodiesterase inhibitor that can exert a nitric oxide-mediated vasodilation effect, so it's considered one of the preferred agents especially in hypoxia induced pulmonary hypertension, can achieve pulmonary vasodilation by enhancing sustained levels of cyclic guanosine monophosphate (cGMP) and nitric oxide. Despite the potential burden of pulmonary hypertension in hemodialysis patients, such agent like sildenafil has limited studies about optimum dose, safety and long term efficacy in End stage renal disease patients on hemodialysis with pulmonary hypertension

NCT ID: NCT03762577 Enrolling by invitation - Clinical trials for Pulmonary Hypertension

Effects of Ground-based Walking Training in Pulmonary Hypertension

Start date: September 12, 2018
Phase: N/A
Study type: Interventional

Pulmonary Hypertension (PH) is a hemodynamic and physiopathological condition that is defined as an increase in pulmonary artery pressure ≥25 mmHg when measured at resting with symptoms such as dyspnea, fatigue, chest pain, and syncope. PH characterized by decreased exercise capacity, quality of life, peripheral muscle strength, balance, and physical inactivity. It is recommended that patients with PH should be included in cardiopulmonary rehabilitation programs in addition to medical treatment. Ground-based walking training is a safe and effective method for COPD patients. In the literature, there are no studies evaluating the effects of ground-based walking training in PH patients. The aim of this project is to determine the effect of ground-based walking training on physical activity, exercise capacity, balance, peripheral muscle strength and quality of life in patients with PH.

NCT ID: NCT03727451 Not yet recruiting - Clinical trials for Pulmonary Hypertension

A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis

Start date: January 2019
Phase: Phase 2
Study type: Interventional

A phase 2b, open label study to assess the safety and efficacy of increasing doses of pulsed, inhaled nitric oxide (iNO) in subjects with pulmonary fibrosis and sarcoidosis on long term oxygen therapy followed by a long term extension study

NCT ID: NCT03726398 Recruiting - Clinical trials for Pulmonary Hypertension

CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH

CRUSADE
Start date: September 1, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

Patients with interstitial lung disease (ILD) and scleroderma who develop pulmonary hypertension (PH) do not fit well into the current classification system and treatments for pulmonary hypertension. This study aims to better understand patients with ILD-PH and scleroderma and to determine if treatment with Macitentan is beneficial.

NCT ID: NCT03707561 Enrolling by invitation - Clinical trials for Pulmonary Hypertension

RUS-registry of PH

Start date: January 2016
Phase:
Study type: Observational [Patient Registry]

Russian National Registry of Patients With Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is a multicenter, observational study of the clinical course and disease management of PAH and CTEPH patients. designed to gather demographic, clinical and prognostic data of routine medical care in prospective manner for newly initiated treatment since Jan 2016. The internet-based registry (www.medibase.pro) fulfills high quality standards through several measures (planned minimum centre contribution of at least 10 patients per year, automated plausibility checks of data at entry, queries, monitoring with source data verification in >50% of participating centers). All consecutive patients diagnosed with World Health Organization Pulmonary Hypertension Groups (WHO Group I) PAH according to specific hemodynamic criteria will be enrolled in participating centers after signing the informed consents. Participating patients will be followed for a minimum of five years from the time of enrollment. It can be applied, among further purposes, for quality assurance: individual centers can confidentially compare their results with the combined outcome of the other centers. It is expected that the registry contributes to optimization of specific drug therapy for PAH and Pulmonary Hypertension (PH).

NCT ID: NCT03683186 Enrolling by invitation - Hypertension Clinical Trials

A Study Evaluating the Long-Term Safety and Efficacy of Ralinepag in Subjects With PAH Via an Open-Label Extension

Start date: September 2018
Phase: Phase 3
Study type: Interventional

Study APD811-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.

NCT ID: NCT03673774 Recruiting - Clinical trials for Pulmonary Hypertension

Impedancemetry in Patients Monitored for Pulmonary Hypertension

HPepic
Start date: August 23, 2017
Phase: N/A
Study type: Interventional

Monocentric cohort study, prospective, evaluating the variability of cardiac output measurement by resting and stress impedancemetry as a prognostic factor for Pulmonary Hypertension